Company Profile

ChemoCentryx, Inc. is an integrated biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. The Company is targeting the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. Its development pipelines include TAVNEOS and Immuno-Oncology. TAVNEOS is for the treatment of severe hidradenitis suppurativa (HS) and seeks to advance TAVNEOS into Phase III clinical development for the treatment of severe HS. The Company's CCX559 is orally-administered investigational inhibitor for programmed death protein 1/programmed death-ligand 1 (PD-1/PD-L1), which is developing for the treatment of various cancers. It markets TAVNEOS (avacopan) as an adjunctive treatment for adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis associated vasculitis, specifically granulomatosis with polyangiitis and microscopic polyangiitis.

Employees

178

Sector

Pharmaceuticals

More about the company

04-29	ChemoCentryx, Inc Proposes Withdrawal of Approval for TAVNEOS Avacopan Capsule 10 Milligrams	CI
24/10/22	ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from S&P Global BMI Index	CI
24/10/22	ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from S&P TMI Index	CI
24/10/22	ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from S&P Biotechnology Select Industry Index	CI
20/10/22	Amgen Completes ChemoCentryx Acquisition	MT
20/10/22	Chemocentryx, Inc. Announces Executive Changes	CI
20/10/22	ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from NASDAQ Composite Index	CI
19/10/22	Amgen Inc. completed the acquisition of ChemoCentryx, Inc. from a group of shareholders.	CI
19/10/22	ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from NASDAQ Biotechnology Index	CI
28/09/22	Swissmedic OKs ChemoCentryx's Combo Therapy For Rare Blood Vessel Disease	MT
18/08/22	Insider Sell: Chemocentryx	MT
18/08/22	UK Agency Recommends Tavneos Combo for Treatment of Rare Blood Vessel Disease	MT
12/08/22	Biotech stocks pin bounce back hopes on M&A boost	RE

10/08/22	Stifel Cuts ChemoCentryx to Hold From Buy, Price Target to $52 From $86	MT
05/08/22	SVB Securities Downgrades ChemoCentryx to Market Perform From Outperform, Adjusts Price Target to $52 From $64	MT
05/08/22	HC Wainwright Downgrades ChemoCentryx to Neutral From Buy, Adjusts Price Target to $52 From $101	MT
05/08/22	Canaccord Genuity Downgrades ChemoCentryx to Hold From Buy; Price Target is $52	MT
04/08/22	Raymond James Downgrades ChemoCentryx to Market Perform From Strong Buy	MT

20/10/22	CHEMOCENTRYX, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
20/10/22	AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX	PR
18/10/22	CHEMOCENTRYX, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	AQ
17/10/22	ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings	GL
17/10/22	ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings	GL

21/10/22	HBM Healthcare rutscht im H1 2022/23 mit 34 Millionen Franken in Verlustzone
21/10/22	HBM Healthcare confirme une perte semestrielle de 34,2 millions
03/10/22	HBM Healthcare prévoit une perte de 34 millions au 1er semestre 2022/23
03/10/22	HBM Healthcare erwartet für H1 2022/23 Nettoverlust von rund 34 Mio Fr.
05/08/22	Coinbase & BlackRock unis, Amgen prend Chemocentryx, Apollo prend Atlas : Planète Bourse du 5 août

Manager	Title	Age	Since
James Bradner CEO	Chief Executive Officer	53	-
Peter Griffith DFI	Director of Finance/CFO	67	-
Jonathan Graham SEC	Corporate Secretary	65	-

ChemoCentryx, Inc. Share Price

Stocks

CCXI

US16383L1061

Pharmaceuticals

Latest news: ChemoCentryx, Inc.

Analysts' recommendations: ChemoCentryx, Inc.

Press Releases: ChemoCentryx, Inc.

News in other languages: ChemoCentryx, Inc.

Quotes and Performance

Managers and Directors: ChemoCentryx, Inc.

Latest insider transactions

Biopharmaceuticals

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
20/10/22	Thomas A. Edwards	Issuer sale	Director	197,514	0.2768%
20/10/22	Markus J. Cappel	Issuer sale	Executive/Senior Manager	308,273	0.4320%
20/10/22	Tausif Butt	Issuer sale	Chief Operating Officer	179,470	0.2515%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CHEMOCENTRYX, INC.	+0.06%	+0.10%	-	-	3.74B
ELI LILLY AND COMPANY	+3.19%	+11.31%	+67.86%	+150.58%	1,263B
JOHNSON & JOHNSON	-0.73%	+3.56%	+44.51%	+85.81%	658B
ABBVIE INC.	+1.41%	+3.24%	+29.22%	+107.83%	521B
ROCHE HOLDING AG	+0.42%	+3.20%	+54.15%	+67.18%	391B
MERCK & CO., INC.	+2.18%	+2.93%	+73.30%	+45.62%	369B
NOVARTIS AG	+1.12%	+4.52%	+35.30%	+58.08%	307B
ASTRAZENECA PLC	+6.96%	+8.86%	+11.27%	+36.62%	290B
AMGEN INC.	+1.15%	+6.09%	+59.59%	+77.06%	252B
GILEAD SCIENCES, INC.	+3.06%	+9.38%	+44.11%	+119.47%	212B
Average	+1.56%	+5.90%	+46.59%	+83.14%	473.55B
Weighted average by Cap.	+1.19%	+6.60%	+50.88%	+98.31%